Clinical trial
LMB-7 Immunotoxin in Treating Patients With Leptomeningeal Metastases
NCT00003020 · Duke University, Other · Completed
Key facts
| NCT number | NCT00003020 |
|---|---|
| Title | LMB-7 Immunotoxin in Treating Patients With Leptomeningeal Metastases |
| Official title | Protocol for a Phase I Study of Intrathecal LMB-7 (Single-Chain Immunotoxin Constructed From Monoclonal Antibody B3-Pseudomonas Exotoxin PE 38) [IND 5863, NSC 658931] in the Treatment of Patients With Leptomeningeal Neoplasms |
| Lead sponsor | Duke University, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Biological |
| Interventions | LMB-7 immunotoxin |
| Enrollment | 24 |
| Start date | Sep 1, 1997 |
| Primary completion | Sep 1, 2000 |
| Completion | Sep 1, 2000 |
| First posted | May 19, 2004 |
| Last update posted | Feb 20, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: